GeoVax (GOVX) Reports 2025 Year-End Financial Results and Provides Business Update
LIVE QUOTE
Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine)
Scheduled to Initiate During the Second Half of This Year
ATLANTA, GA - April 15, 2026 (NEWMEDIAWIRE)...
Report: AI Powered Review on GeoVax (GOVX) $1.15
In our view, a research report is designed to gather information on publicly traded companies from press releases, management presentations (including power points), SEC...
Biotech Stock Review is Back! Timing Feels Perfect. 4 Companies Added to Watch List.
Biotech 12 Pack Watch List to be Released.
Cabaletta (CABA) $3.07, GeoVax (GOVX) $1.14, PolyPid (PYPD) $4.68, Replimune (REPL) $2.17.
In 2020, we Released the "Biotech...
GeoVax (GOVX) Reports Both Favorable Safety and “It’s Working” News for its Cancer...
Official Headline is "GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck...
GeoVax Report (GOVX) $0.69. From Crystal Research.
July 2025 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)
Crystal Research Associates has issued a 16-page Company Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Snapshot...
GeoVax (GOVX) Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen...
https://youtu.be/4LffUyg6yE8?si=G8_kZMce8yHGCxKp
GEO-CM04S1 Offers Solution to Overcome HHS-Cited mRNA Deficiencies - Potentially Offering Broader, More Durable Protection
ATLANTA, GA - August 7, 2025 (NEWMEDIAWIRE) - GeoVax Labs,...
Cardiol’s (CRDL) Game-Changing Solution for Heart Inflammation? | David Elsley CEO – Video Interview
In this interview with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), we explore the company's innovative approach to...
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier 44-page report, we printed it out and...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value of award to GeoVax and its CRO partner total approximately $367-388 million
BARDA-funded...
GeoVax Receives Massive $300+ Million BARDA Project NextGen Award!
Are we happy, you betcha!
We just got back from St Croix where the team from the Beverage Stock Review visited the Mutiny Island Vodka...
Latest article
Party Time at uniQure (QURE). $48 up 443%
No Bells, no Baskets. But Still not out of the Woods!
We’re Up 360% in Six Weeks. Replimune (REPL).
That's a Gain of $604 Million, and That Ain't Bad!
Six brokerage firms downgraded Replimune (REPL), around the same time we added it to...
GeoVax (GOVX) Conference Call and Transcript.
Excellent Presentation. You Can Listen for 40 Minutes, or Read it in About Ten, Halleluiah.
Guess what we'll choose to do?
We have no...
